Patients treated with frontline programmed death 1 inhibitors who had 18F-BMS-986229 accumulation in any lesions on PET imaging had longer progression-free survival than patients without tracer accumulation in any lesions (median progression-free survival, 28.4 vs. 9.9mo), though the small sample ...
18F-BMS-986229 是一种大环肽,与 PD-L1 有很高的亲和力,与受体结合紧密,脱靶速度慢,能迅速从非 PD-L1 表达组织中清除,能以更高的产量分离出来,同时合成难度也低于 18F-BMS-986192。18F-BMS-986229 的临床前评估表明,它能在体外和体内与表达 PD-L1 的组织特异性结合。本研究是首次针对 GEC患者进行的PD-L1靶...
18F-BMS-986229 是一种大环肽,与 PD-L1 有很高的亲和力,与受体结合紧密,脱靶速度慢,能迅速从非 PD-L1 表达组织中清除,能以更高的产量分离出来,同时合成难度也低于 18F-BMS-986192。18F-BMS-986229 的临床前评估表明,它能在体外和体内与表达 PD-L1 的组织特异性结合。本研究是首次针对 GEC患者进行的PD-L1靶...
Determining PD-L1 status by whole body, non-invasive PD-L1 PET imaging with 18F-BMS-986229 tracer infusion may be a way to circumvent limitations to PD-L1 IHC such as poor tissue availability; discrepant PD-L1 IHC results among different tumors within the same patient; and inability to ...
Better methods of non-invasive, comprehensive PD-L1 evaluation are needed.Methods:This is a prospective, pilot PET study of the positron-emitting agent18F-BMS-986229, a macrocyclic peptide with high affinity for PD-L1. Patients were administered18F-BMS-986229 intravenously and underwent whole body ...